Yanagi Teruki

写真a

Title

Associate Professor
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Associate Professor  

To the head of this page.▲

Academic degree 【 display / non-display 】

  • Hokkaido University -  PhD

To the head of this page.▲

Affiliated academic organizations 【 display / non-display 】

  • 　
    　
    　
     

    THE JAPANESE SOCIETY FOR INVESTIGATIVE DERMATOLOGY 

  • 　
    　
    　
     

    THE JAPANESE DERMATOLOGICAL ASSOCIATION 

  • 　
    　
    　
     

    THE JAPANESE CANCER ASSOCIATION 

To the head of this page.▲

Research Interests 【 display / non-display 】

  • 皮膚腫瘍学

To the head of this page.▲

Research Areas 【 display / non-display 】

  • Life Science / Dermatology

  • Life Science / Tumor biology

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Dermoscopic Features of Porocarcinoma: Report of 11 Cases and Review of the Literature

    Miyamoto, K; Yanagi, T; Maeda, T; Tokuchi, K; Hsu, CY; Ujiie, H

    INDIAN JOURNAL OF DERMATOLOGY ( Indian Journal of Dermatology )  71 ( 2 ) 145 - 150   2026.03 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Brain Metastasis From Angiosarcoma of the Scalp: Report of Three Cases.

    Kudo M, Shirato R, Yanagi T, Yamagata W, Yogi A, Ohira A, Iwamoto R, Takahashi K

    The Journal of dermatology ( Journal of Dermatology )  52 ( 9 ) 1456 - 1460   2025.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Prevalence of FOXA1 and ERBB2 activating mutations in extramammary Paget's disease: A retrospective multicenter analysis of 99 cases from Japanese and Taiwanese cohorts.

    Omi M, Takeichi T, Okuno Y, Hsu CK, Wu CL, Chang YH, Mori S, Yamashita Y, Miyazaki A, Taira T, Yanagi T, Fukuda K, Noda T, Suzuki Y, Muro Y, Akiyama M

    Journal of dermatological science ( Journal of Dermatological Science )    2025.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Eribulin inhibits tumor growth of two novel patient-derived xenograft models of Merkel cell carcinoma

    Miyamoto, K; Yanagi, T; Maeda, T; Kitamura, S; Nishihara, H; Iwamoto, R; Takahashi, K; Ujiie, H

    JOURNAL OF DERMATOLOGICAL SCIENCE ( Journal of Dermatological Science )  119 ( 2 ) 82 - 89   2025.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer with a poor prognosis in advanced cases. Despite reported sensitivities to chemotherapy and immunotherapy, response rates remain limited to approximately 50 % of cases. Although developing novel therapeutic strategies against MCC has been desired, few preclinical models, including cell lines and patient-derived xenografts (PDXs), are available. OBJECTIVES: This study aimed to establish novel preclinical research models and develop novel therapeutic strategies for MCC. METHODS: We analyzed 19 clinical MCC samples in our department. Moreover, to establish novel PDX tumors, we transplanted MCC tissues from Japanese patients into immunodeficient NOD/SCID mice. RESULTS: Histopathological analyses of 19 clinical MCC samples in our department revealed the tumors to either be infected with the Merkel cell polyomavirus or have lost the expression of tumor suppressors (tumor protein p53 [p53] or RB transcriptional corepressor 1 [Rb1]). To establish novel PDX tumors, we transplanted MCC tissues from Japanese patients into immunodeficient NOD/SCID mice. Two MCC-PDX tumors were successfully implanted (MCC-PDX-MK1 and -MK2), and their histopathological and genetic characteristics were consistent with those of the original tumor. As in vivo preclinical treatments, we administered cisplatin, etoposide, docetaxel, or eribulin to the NOD/SCID mice. Eribulin showed antitumor activity in both MCC-PDX models. CONCLUSION: Two MCC-PDX models were established successfully, and therapeutic experiments suggest that eribulin could inhibit MCC tumor growth.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025

    Fukushima, S; Ito, T; Asai, J; Igaki, H; Tanaka, R; Namikawa, K; Hayashi, A; Minagawa, A; Miyagawa, T; Miyashita, A; Ogata, D; Okumura, M; Kiniwa, Y; Goto, H; Namiki, T; Hashimoto, H; Hida, T; Hirata, T; Maeda, T; Matsuzawa, T; Yanagi, T; Sugimoto, K; Kimura, E; Koga, H; Uchi, H; Miyagaki, T; Nakamura, Y; Inozume, T

    JOURNAL OF DERMATOLOGY ( Journal of Dermatology )  52 ( 8 ) e666 - e697   2025.08 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

display all >>

To the head of this page.▲

Other Papers 【 display / non-display 】

  • CDK4/6 in extramammary Paget disease

    柳輝希

    臨床皮膚科   77 ( 5 ) 54 - 57   2023.04  [Refereed]

     

    J-GLOBAL

  • Two cases of basal cell nevus syndrome responded to imiquimod

    小川弘記, 北村真也, 田中有沙, 山賀三紗子, 平野瑶子, 瀬尾拓志, 葭本倫大, 加藤直子, 柳輝希, 氏家英之

    臨床皮膚科   77 ( 4 ) 347 - 352   2023.04  [Refereed]

     

    J-GLOBAL

  • Type 1 diabetes mellitus in a melanoma patient treated with adjuvant nivolumab therapy

    Takuya Maeda, Shinya Kitamura, Teruki Yanagi, Atsushi Narahira, Kodai Miyamoto, Hiroo Hata, kyu Yong Cho, Hiraku Kameda, Akinobu Nakamura, Hiroshi Shimizu

    Journal of Cutaneous Immunology and Allergy   2 ( 6 ) 176 - 177   2019.12  [Refereed]

     

    DOI Open Access

  • 扁平上皮癌におけるTripartite motif‐containing protein 29(TRIM29)の検討

    柳輝希, 秦洋郎, 北村真也, 清水宏, 柳紘子, 本間明宏, 渡部昌, 畠山鎮次

    日本皮膚科学会雑誌   129 ( 5 ) 1170 - 1170   2019.05

     

    J-GLOBAL

  • 扁平上皮におけるTripartite motif‐containing protein 29(TRIM29)の機能解析

    柳輝希, 秦洋郎, 北村真也, 今福恵輔, 清水宏, 柳紘子, 本間明宏, 渡部昌, 畠山鎮次

    日本皮膚科学会雑誌   129 ( 1 ) 45 - 45   2019.01

     

    DOI J-GLOBAL

display all >>

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

  • Development of a novel therapeutic strategy for angiosarcoma through drug screening

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2023.04  -  2026.03 

    Direct: 3,600,000 (YEN)  Overheads: 4,680,000 (YEN)  Total: 1,080,000 (YEN)

  • Grant-in-Aid for Scientific Research(C)

    Project Year: 2022.04  -  2025.03 

    Direct: 3,300,000 (YEN)  Overheads: 4,290,000 (YEN)  Total: 990,000 (YEN)

  • Grant-in-Aid for Scientific Research(B)

    Project Year: 2021.04  -  2024.03 

    Direct: 13,300,000 (YEN)  Overheads: 17,290,000 (YEN)  Total: 3,990,000 (YEN)

  • Genome-wide screening of the key molecules for metastasizing collagen VII-deficient squamous cell carcinoma.

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2019.04  -  2022.03 

    Direct: 3,300,000 (YEN)  Overheads: 4,290,000 (YEN)  Total: 990,000 (YEN)

  • Genome-wide screening of the key molecules for metastasizing collagen VII-deficient squamous cell carcinoma.

    Grant-in-Aid for Scientific Research(C)

    Project Year: 2019.04  -  2022.03 

    Investigator(s): Nakamura Hideki 

    Direct: 3,300,000 (YEN)  Overheads: 4,290,000 (YEN)  Total: 990,000 (YEN)

    　View Summary

    The aim of this study was to elucidate the metastatic mechanism of squamous cell carcinoma (SCC) arising in patients with dystrophic epidermolysis bullosa (DEB) caused by mutations in type 7 collagen (COL7) gene. DEB patient model keratinocytes with a comprehensive gene-editing did not develop metastasis when transplanted subcutaneously in mice, but the subcutaneous tumors of DEB patient model showed an overall irregular structure, surrounding fibrosis, and hypervascularization compared to subcutaneous tumors of normal keratinocytes. These results suggest that subcutaneous tumors in DEB patient model induce changes in the surrounding tissue environment via abnormal construction of the basement membrane, and that these changes may contribute to the metastatic mechanism of SCC in DEB patients.

display all >>

To the head of this page.▲